These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31169803)

  • 21. Basal insulins: Pharmacological properties and patient perspectives.
    Abrahamson MJ
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concentrated insulins: History and critical reappraisal.
    Heinemann L; Beals JM; Malone J; Anderson J; Jacobson JG; Sinha V; Corrigan SM
    J Diabetes; 2019 Apr; 11(4):292-300. PubMed ID: 30264527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
    Ericsson Å; Lundqvist A
    Appl Health Econ Health Policy; 2017 Apr; 15(2):237-248. PubMed ID: 28063135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?
    Bell DS
    Drugs; 2007; 67(13):1813-27. PubMed ID: 17722952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2022 Nov; 64(1663):177-184. PubMed ID: 36384763
    [No Abstract]   [Full Text] [Related]  

  • 28. What is the role of concentrated insulin in diabetes management?
    Mospan CM
    JAAPA; 2016 Jun; 29(6):16-8. PubMed ID: 27228041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic.
    Williams DM; Shrikrishnapalasuriyar N; Syed W; Yin WL; Chudleigh R; Bain SC; Price DE; Stephens JW
    Diabetes Metab Syndr; 2018 Nov; 12(6):1079-1082. PubMed ID: 30006093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes.
    Rendell M
    Drug Des Devel Ther; 2017; 11():1209-1220. PubMed ID: 28458515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits.
    Coscelli C; Iacobellis G; Calderini C; Carleo R; Gobbo M; Di Mario U; Leonetti F; Galluzzo A; Pirrone V; Lunetta M; Casale P; Paleari F; Falcelli C; Valle D; Camporeale A; Merante D
    Acta Diabetol; 2003 Dec; 40(4):187-92. PubMed ID: 14740279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Insulins and New Aspects in Insulin Delivery.
    Woo VC
    Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
    Blumer I; Pettus JH; Santos Cavaiola T
    Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
    Charbonnel B; Bertolini M; Tinahones FJ; Domingo MP; Davies M
    J Diabetes Complications; 2014; 28(6):880-6. PubMed ID: 25130920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
    Baron HL
    J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.